• 1
    Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 2001; 40: 231252.
  • 2
    Ringden O. Allogeneic bone marrow transplantation for hematological malignancies—controversies and recent advances. Acta Oncol. 1997; 36: 549564.
  • 3
    Burnett AK. Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Cancer Chemother Pharmacol. 2001; 48(Suppl 1): S53S58.
  • 4
    Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998; 351: 700708.
  • 5
    Edenfield WJ, Gore SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol. 1999; 26: 2134.
  • 6
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 7
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896903.
  • 8
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58: 41734179.
  • 9
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339: 16491656.
  • 10
    Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997; 90: 29782986.
  • 11
    Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs. autologous stem cell transplantation vs. chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 1996; 10: 18741882.
  • 12
    Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217223.
  • 13
    Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999; 341: 1421.
  • 14
    Andrykowski MA, Henslee PJ, Farrall MG. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989; 4: 7581.
  • 15
    Jenkins PL, Linington A, Whittaker JA. A retrospective study of psychosocial morbidity in bone marrow transplant recipients. Psychosomatics. 1991; 32: 6571.
  • 16
    Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant. 1993; 11: 319327.
  • 17
    Watson M, Wheatley K, Harrison GA, et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer. 1999; 86: 12311239.
  • 18
    Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1997; 20: 307315.
  • 19
    Sox H, Blatt MA, Higgins MC, Marton KI. Medical decision making. London: Butterworth and Company, 1988.
  • 20
    Reiffers J, Gaspard MH, Maraninchi D, et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol. 1989; 72: 5763.
  • 21
    McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med. 1975; 293: 211215.
  • 22
    Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2—building a tree. Med Decision Making. 1997; 17: 126135.
  • 23
    Gotay CC, Muraoka MY. Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst. 1998; 90: 656667.
  • 24
    Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971–1988: predictors for later psychologic distress. Cancer. 1997; 80: 19361944.
  • 25
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 33023317.
  • 26
    Statistics Canada. Life expectancy. Ottawa: Statistics Canada, 1991.
  • 27
    Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997; 336: 897904.
  • 28
    Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med. 1982; 73: 883888.
  • 29
    Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med. 1998; 339: 380386.
  • 30
    Moskowitz AJ, Dunn VH, Lau J, Pauker SG. Can “hypersimplified” decision trees be used instead of Markov models [abstract]? Med Decision Making. 1984; 4: 530.
  • 31
    Hertenstein B, Heil G, Heimpel H. Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Ann Hematol. 1996; 72: 223230.
  • 32
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health care and medicine. New York: Oxford University Press, 1996.